Gossamer Bio (GOSS)
(Real Time Quote from BATS)
$1.06 USD
+0.03 (2.91%)
Updated Jul 22, 2024 01:02 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GOSS 1.06 +0.03(2.91%)
Will GOSS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
Other News for GOSS
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Video: Tuesday 6/25 Insider Buying Report: GOSS, EXFY
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH